All News

Pfizer settles its litigation against Teva Pharmaceuticals regarding Pfizer's patent covering the use of Viagra.

Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.

AstraZeneca issues a statement regarding the launch of esomeprazole strontium in the United States.

AstraZeneca's MedImmune will collaborate with Johns Hopkins University in both biologics and small-molecule projects.

Merck's new facility for aseptic production in Reinbek, Germany is scheduled to be completed in 2016.

Almost 400 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections.

Agency issues precautionary recall due to manufacturing fault.

Agency issues precautionary recall due to manufacturing fault.

FDA details efforts to evaluate potential risks from use of nanomaterials in drug products and discuss analytical considerations, impact on stability, safety, and toxicology effects.

Johnson&Johnson will open a network of partnering offices across the UK.

GlaxoSmithKline plans to expand its facilities in Ware and Worthing in the United Kingdom and will build a new facility for manufacturing innovation.

Roche and Prothena sign deal worth up to $600 million to develop and commercialize antibodies that target alpha-synuclein.

Teva Pharmaceutical Industries releases a financial outlook for 2014 based on two possible scenarios concerning its multiple-sclerosis drug Copaxone (glatiramer acetate).

BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.

Octapharma and Pfizer form an agreement for the future marketing and commercialization of human prothrombin complex concentrate.

GSK forms the Oncology Clinical and Translational Consortium, a scientific research network comprised of six international cancer centers.

OGD is under pressure to improve review operations.

Bristol-Myers Squibb has elected Thomas Lynch, Jr., MD to its board of directors.

Alvotech plans investment in biosimilars portfolio and manufacturing facility.

LSNE appoints Shawn Cain as COO, a new position within the company.

EMA revises its polices on fee reductions for orphan drugs for 2014.

TxCell has received manufacturing accreditation status of its cell-therapy production site in Besancon, France, from the French National Agency for Drug Safety (ANSM).

SGS Life Science Services announced that its bioanalytical laboratory in Poitiers, France has received GMP certification, following approval from ANSM.

Drug Quality and Security Act gives FDA authority over compounding pharmacies.

The international “Fight the Fakes” campaign will raise awareness about the dangers of counterfeit medicines.

The Indiana Biosciences Research Institute will accelerate collaboration and focus on human-health solutions.

Additional companies join Merck KGaA and Neviah Genomics in the Israel BioIncubator.

Almac releases an enhanced third-party logistics customer billing application.

GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.

GlaxoSmithKline plans to invest nearly $41 million to expand its operations at its facility in Montrose, the United Kingdom.